6533b873fe1ef96bd12d5942
RESEARCH PRODUCT
Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial.
Paolo PronzatoRicardo RossoPeter Barrett-leeJosé A. Moreno-nogueiraPeter OstlerAlain BolsCarin C.d. Van Der RijtEnrico CortesiCarlos Freire De Oliveirasubject
AdultCancer Researchmedicine.medical_specialtySurvivalAnemiaPopulationAntineoplastic AgentsBreast NeoplasmsAcademia–Pharma Intersectlaw.inventionbreast cancer; anemia; erythropoietin; hemoglobin; survival; fatigueHemoglobinsBreast cancerRandomized controlled trialstomatognathic systemlawInternal medicinehemic and lymphatic diseasesBreast CancermedicineClinical endpointHumansBlood TransfusionHemoglobinProspective StudieseducationSurvival rateErythropoietinFatigueAgededucation.field_of_studybusiness.industryEpoetin alfavirus diseasesAnemiaMiddle Agedmedicine.diseasedigestive system diseasesRecombinant ProteinsSurgeryEpoetin AlfaOncologyErythropoietinHematinicsFemalebusinesstherapeuticsmedicine.drugdescription
This study evaluated the effects of epoetin alfa on patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy. Early intervention with epoetin alfa was well tolerated and improved anemia-related patient-reported outcomes.
year | journal | country | edition | language |
---|---|---|---|---|
2010-08-01 |